Cargando…

Value of central review of RECIST v1.1 outcomes in the AGITG INTEGRATE randomised phase 2 international trial for advanced oesophago-gastric cancer

PURPOSE: Activity estimates should be accurately evaluated in phase 2 clinical trials to ensure appropriate decisions about proceeding to phase 3 trials. RECIST v1.1. progression-free survival (PFS) is a common endpoint in oncology; however, it can be influenced by assessment criteria and trial desi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sjoquist, Katrin M., Martin, Andrew, Pavlakis, Nick, Goldstein, David, Tsobanis, Eric, Moses, Daniel, Maher, Richard, Hague, Wendy, Gebski, Val, Stockler, Martin R., Simes, R. John
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10349725/ https://www.ncbi.nlm.nih.gov/pubmed/36310299 http://dx.doi.org/10.1007/s00432-022-04404-4

Ejemplares similares

INTEGRATE II: randomised phase III controlled trials of regorafenib containing regimens versus standard of care in refractory Advanced Gastro-Oesophageal Cancer (AGOC): a study by the Australasian Gastro-Intestinal Trials Group (AGITG)
por: Lam, Lyn Ley, et al.
Publicado: (2023)

The effect of anti-angiogenic agents on overall survival in metastatic oesophago-gastric cancer: A systematic review and meta-analysis
por: Chan, David L., et al.
Publicado: (2017)

AGITG MASTERPLAN: a randomised phase II study of modified FOLFIRINOX alone or in combination with stereotactic body radiotherapy for patients with high-risk and locally advanced pancreatic cancer
por: Oar, Andrew, et al.
Publicado: (2021)

Docetaxel plus cetuximab as second-line treatment for docetaxel-refractory oesophagogastric cancer: the AGITG ATTAX2 trial
por: Tebbutt, N C, et al.
Publicado: (2013)

Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial
por: Tebbutt, N C, et al.
Publicado: (2010)

VEGF-A, VEGFR1 and VEGFR2 single nucleotide polymorphisms and outcomes from the AGITG MAX trial of capecitabine, bevacizumab and mitomycin C in metastatic colorectal cancer
por: Chionh, Fiona, et al.
Publicado: (2022)

Comparison of tumor assessments using RECIST 1.1 and irRECIST, and association with overall survival
por: Manitz, Juliane, et al.
Publicado: (2022)

Comparison of RECIST 1.0 and RECIST 1.1 in Patients with Metastatic Cancer: A Pooled Analysis
por: Kim, Jung Han, et al.
Publicado: (2015)

TOPGEAR: a randomised phase III trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer (an international, intergroup trial of the AGITG/TROG/EORTC/NCIC CTG)
por: Leong, Trevor, et al.
Publicado: (2015)

Response Evaluation and Survival Prediction Following PD‐1 Inhibitor in Patients With Advanced Hepatocellular Carcinoma: Comparison of the RECIST 1.1, iRECIST, and mRECIST Criteria
por: Zhou, Meng, et al.
Publicado: (2021)

Patient-reported outcome (PRO) results from the AGITG DOCTOR trial: a randomised phase 2 trial of tailored neoadjuvant therapy for resectable oesophageal adenocarcinoma
por: Mercieca-Bebber, R., et al.
Publicado: (2022)

Comparison of the RECIST 1.0 and RECIST 1.1 in Non-Small Cell Lung Cancer Treated with Cytotoxic Chemotherapy
por: Choi, Hyun Chang, et al.
Publicado: (2015)

Comparison of the RECIST 1.0 and RECIST 1.1 in patients treated with targeted agents: a pooled analysis and review
por: Kim, Jung Han
Publicado: (2016)

Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis
por: Mulkey, Flora, et al.
Publicado: (2020)

Comparison of RECIST 1.1 and iRECIST in Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
por: Park, Hyo Jung, et al.
Publicado: (2021)

Challenges of international oncology trial collaboration—a call to action
por: Tang, Monica, et al.
Publicado: (2019)

10-Year axillary recurrence in the RACS SNAC1 randomised trial of sentinel lymph node-based management versus routine axillary lymph node dissection
por: Campbell, Ian, et al.
Publicado: (2023)

Patterns of response in metastatic NSCLC during PD‐1 or PD‐L1 inhibitor therapy: Comparison of the RECIST 1.1 and iRECIST criteria
por: Liang, Hongge, et al.
Publicado: (2020)

MONARCC: a randomised phase II study of panitumumab monotherapy and panitumumab plus 5-fluorouracil as first-line therapy for RAS and BRAF wildtype metastatic colorectal cancer: a study by the Australasian Gastrointestinal Trials Group (AGITG)
por: Siu, Ho Wai Derrick, et al.
Publicado: (2021)

RECIST 1.1 and lesion selection: How to deal with ambiguity at baseline?
por: Iannessi, Antoine, et al.
Publicado: (2021)

Propofol Sedation for Oesophago-Gastro-Duodenoscopy
por: Watt, J. M., et al.
Publicado: (1999)

RECIST rules
por: Sohaib, Aslam
Publicado: (2012)

Cancer Response Criteria and Bone Metastases: RECIST 1.1, MDA and PERCIST
por: Costelloe, Colleen M., et al.
Publicado: (2010)

Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancer
por: Price, T J, et al.
Publicado: (2015)

Clustering on longitudinal quality‐of‐life measurements using growth mixture models for clinical prognosis: Implementation on CCTG/AGITG CO.20 trial
por: Zhang, Jiahui, et al.
Publicado: (2022)

Tumor response evaluation criteria for HCC (hepatocellular carcinoma) treated using TACE (transcatheter arterial chemoembolization): RECIST (response evaluation criteria in solid tumors) version 1.1 and mRECIST (modified RECIST): JIVROSG-0602
por: Sato, Yozo, et al.
Publicado: (2013)

Self-reported health-related quality of life is an independent predictor of chemotherapy treatment benefit and toxicity in women with advanced breast cancer
por: Lee, C K, et al.
Publicado: (2010)

The pattern of recurrence of adenocarcinoma of the oesophago-gastric junction
por: Wayman, J, et al.
Publicado: (2002)

Double stenting for malignant oesophago-respiratory fistula
por: Włodarczyk, Janusz, et al.
Publicado: (2016)

Immune Checkpoint Inhibition in Oesophago-Gastric Carcinoma
por: Högner, Anica, et al.
Publicado: (2021)

The Modified Response Evaluation Criteria in Solid Tumors (RECIST) Yield a More Accurate Prognoses Than the RECIST 1.1 in Hepatocellular Carcinoma Treated with Transarterial Radioembolization
por: Lee, Jae Seung, et al.
Publicado: (2020)

The α-RECIST (RECIST 1.1 Combined With Alpha Fetoprotein): A Novel Tool for Identifying Tumor Response of Conversion-Radiotherapy for Unresectable Hepatocellular Carcinoma Before Hepatectomy
por: Xu, Ying, et al.
Publicado: (2022)

Accuracy of oncologists’ estimates of expected survival time in advanced cancer
por: Nahm, Sharon H, et al.
Publicado: (2023)

RECIST revised: implications for the radiologist. A review article on the modified RECIST guideline
por: van Persijn van Meerten, Els L., et al.
Publicado: (2009)

RECIST 1.1 versus mRECIST for assessment of tumour response to molecular targeted therapies and disease outcomes in patients with hepatocellular carcinoma: a systematic review and meta-analysis
por: Yu, Hongli, et al.
Publicado: (2022)

mRNA profiling of the cancer degradome in oesophago–gastric adenocarcinoma
por: Baren, J P, et al.
Publicado: (2012)

Comparison of Radiological Tumor Response Based on iRECIST and RECIST 1.1 in Metastatic Clear-Cell Renal Cell Carcinoma Patients Treated with Programmed Cell Death-1 Inhibitor Therapy
por: Zheng, Bingjie, et al.
Publicado: (2021)

Can we predict discordant RECIST 1.1 evaluations in double read clinical trials?
por: Beaumont, Hubert, et al.
Publicado: (2023)

SPAR – a randomised, placebo-controlled phase II trial of simvastatin in addition to standard chemotherapy and radiation in preoperative treatment for rectal cancer: an AGITG clinical trial
por: Jameson, Michael B., et al.
Publicado: (2019)

Optimising Multimodality Treatment of Resectable Oesophago-Gastric Adenocarcinoma
por: Suwaidan, Ali Abdulnabi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5h66sasfckd2jcf2d94pn2ahia